{"id":4501,"date":"2025-06-14T09:48:21","date_gmt":"2025-06-14T15:48:21","guid":{"rendered":"https:\/\/allphasepharma.com\/dir\/?p=4501"},"modified":"2025-06-28T23:22:55","modified_gmt":"2025-06-29T05:22:55","slug":"about-a-prepared-mind-in-rd","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2025\/06\/14\/4501\/about-a-prepared-mind-in-rd\/","title":{"rendered":"About A Prepared Mind – In R&D"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

\u201cChance favors the prepared mind\u201d is the short form of a statement by Louis Pasteur which actually reads: \u201cIn the fields of observation chance favours only the prepared mind\u201d or \u201d Dans les champs de l’observation le hasard ne favorise que les esprits prepares\u201d. [1]<\/a><\/p>\n\n\n\n

There is no better example of the wisdom of this phrase than the discovery of X-rays by Wilhelm Conrad R\u00f6ntgen.  When he worked with a vacuum tube he noticed the radiation-emitting feature of his experimental set-up almost immediately.  Pictures of his wife\u2019s hand and later, the hand of the famous anatomist Koelliker, showed the bony anatomy; news of his discovery made it around the world in record time. <\/p>\n\n\n\n

R\u00f6ntgen was not the first to experiment with the Crookes or Hittorf cathode ray tubes.  Other scientists came very close to discovering X-rays but R\u00f6ntgen\u2019s publication in 1895 was the first.  A prepared mind\u2026.<\/p>\n\n\n\n

Arthur Willis Goodspeed, professor of physics at the Univ of Pennsylvania was probably the first to produce an X-ray image however he did not recognize the significance of his discovery.  While tinkering with a Crookes tube at the University of Pennsylvania, he took an X-ray picture of a coin by accident.  He kept the picture but did not pursue and investigate.  When he learned about R\u00f6ntgen\u2019s paper, he reproduced his \u2018coin X-ray\u2019 confirming that it was not an artifact but a product of the same rays described by R\u00f6ntgen.  Later he quibbed that R\u00f6ntgen\u2019s \u2018X-rays\u2019 could have been known as \u2018Goodspeed rays\u2019. He stated that \u201cBecause of our laxity in not following the matter up we do not claim any credit whatsoever\u201d.   A case of a less prepared mind\u2026[2]<\/a><\/p>\n\n\n\n

While Goodspeed was gracious in defeat, others held grudges.  The brilliant physicist Philip Lenard had collaborated with R\u00f6ntgen and bitterly resented R\u00f6ntgen\u2019s fame and Nobel prize in 1901; although he was awarded a Nobel in 1903, the feud – highly politicized – continued till Lenard\u2019s death in 1947. <\/p>\n\n\n\n

FYI, pictures of Goodspeed\u2019s coin X-rays are on display at the Peabody museum in New Haven.  The history of Goodspeed\u2019s \u2018accidental\u2019 discovery, the importance of which he had not recognized, is well described in various articles.  Here are some references for the interested reader [3]<\/a>, [4]<\/a><\/p>\n\n\n\n

In this blog we want to highlight two other aspects of R\u00f6ntgen\u2019s work. <\/p>\n\n\n\n

First, his description of the physico-chemical characteristics of X-rays.  His publication \u201cEine Neue Art von Strahlen\u201d or \u2018A new Kind of Rays\u201d describes in amazing detail the character of these rays: attenuation by materials as a function of atomic density; lack of reflection, lack of convergence by lenses, and lack of deflection in strong magnetic fields.[5]<\/a>  <\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

R\u00f6ntgen soon followed up with a second publication providing further details [6]<\/a> <\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Secondly, R\u00f6ntgen did not take out a patent on his discovery \u2013 actually he refused to benefit financially.\u00a0 This made X-ray technology available for anyone to use, improve and monetize.\u00a0 News about X-rays spread with lightening speed as its use in medicine was obvious [7]<\/a>.\u00a0 X-ray machines were seemingly everywhere in the Old and New World in record time.\u00a0 Case in point: the use of the new technology in Philadelphia, well documented for the turn of the century and later.\u00a0 In fact, the Pennsylvania Hospital in Philadelphia had an X-ray machine in 1897.<\/p>\n\n\n\n

X-rays were used to take pictures of bones, fractures, foreign bodies but also for other purposes [8]<\/a>.  I was amazed to read that the famous violin virtuoso, Josef Joachim had a chest X-rays taken in Berlin prior to his death in 1907.  His pulmonary findings were read by equally famous Berlin physicians who diagnosed pneumonia consistent with \u2018actinomycosis\u2019. How could anyone have come up with this diagnosis?  Joachim was known to have a habit of chewing on grass leaves, hence the idea that his pulmonary infection could be caused by this slow-growing pathogen is not totally off-base.  However, identification and classification of actinomyces spp were by no means established in 1907, even on culture.  And we don\u2019t know what was actually cultured. Another riddle wrapped in a mystery inside an enigma it seems.<\/p>\n\n\n\n

REFERENCES<\/strong>
[1]<\/a> Lecture, University of Lille (7 December 1854) according to https:\/\/en.wikiquote.org\/wiki\/Louis_Pasteur<\/a>.  Accessed 6\/12\/25
[2]<\/a> Busch U. Der erste Strahlenunfall der Geschichte.  https:\/\/www.drg.de\/de-DE\/2365\/erster-strahlenunfall\/<\/a>  accessed 6\/13\/25
[3]<\/a> Walden T. The first radiation accident in America: a centennial account of the x-ray photograph made in 1890.  Radiology 181: 1991
[4]<\/a> Thomas A.  The history of radiology.  Oxford University Press.  2013.  Chapter 1: Wilhelm R\u00f6ntgen and the discovery.
[5]<\/a> Roentgen W.  .  Eine neue Art von Strahlen. 1895. https:\/\/archive.org\/details\/b30475697\/page\/8\/mode\/2up?view=theater
[6]<\/a> Rontgen W.   Ueber eine neue Art von Strahlen. Zweite Mitteilung.  Ann Phys Chem. N. F. 64. 2: 1, 1896
[7]<\/a> Theerman P.  See-Through Science: The Rise of the X-Ray.  https:\/\/nyamcenterforhistory.org\/2014\/11\/07\/see-through-science-the-rise-of-the-x-ray\/<\/a>  Accessed 6\/12\/25
[8]<\/a> Howell \u2013 Early clinical use of the X-ray.  Transactions Am Clin Climatol Assoc 127: 341, 2016<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

\u201cChance favors the prepared mind\u201d is the short form of a statement by Louis Pasteur which actually reads: \u201cIn the fields of observation chance favours only the prepared mind\u201d or \u201d Dans les champs de l’observation le hasard ne favorise que les esprits prepares\u201d. [1] There is no better example Continue reading About A Prepared Mind – In R&D<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":4511,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[140,18],"tags":[1271,2252,163,2253,2247,1583,2246,2251,2256,2254,2255,2249,2248,2250,2244,2243,2245],"class_list":["post-4501","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interesting_facts","category-the_viewpoint","tag-allphase-pharma-consulting","tag-cathode-ray-tube","tag-churchill","tag-crookes-tube","tag-goodspeed","tag-harald-reinhart","tag-history-of-x-rays","tag-hittdorf-tube","tag-koelliker","tag-nobel-prize-physics-1901","tag-pasteur","tag-peabody-museum","tag-pennsylvania-hospital","tag-philipp-lenard","tag-roentgen","tag-rontgen","tag-x-rays"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/06\/HR-BLOG-ROENTGEN-2.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-1aB","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1287,"url":"https:\/\/allphasepharma.com\/dir\/2015\/03\/05\/1287\/the-pneumococcus-prominent-microbiologists-contributions-and-cross-connections\/","url_meta":{"origin":4501,"position":0},"title":"The Pneumococcus, Prominent Microbiologists, Contributions and Cross-Connections","author":"Harald","date":"March 5, 2015","format":false,"excerpt":"\u2018He who knows syphilis knows medicine\u2019 goes the saying. In a similar way this adage could be applied to the Pneumococcus, aka Streptococcus pneumoniae, Diplococcus pneumoniae or Diplococcus lanceolatus by saying \u201cHe who knows S. pneumoniae knows microbiology\u201d. Many \u2018big names\u2019 studied the\u00a0organism. \u00a0Their work on the Pneumococcus led to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"PNEUMOCOCCUS copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/03\/PNEUMOCOCCUS-copy.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1769,"url":"https:\/\/allphasepharma.com\/dir\/2015\/07\/28\/1769\/the-demise-of-kb001-part-2-an-anti-pseudomonas-antibody-hits-the-dust-instead-of-paydirt\/","url_meta":{"origin":4501,"position":1},"title":"The Demise of KB001 (Part 2): An Anti-Pseudomonas Antibody Hits the Dust (instead of Paydirt)","author":"Harald","date":"July 28, 2015","format":false,"excerpt":"FOR\u00a0PART 1, CLICK HERE Should we assume that the results of this Global Epi Study were the reason why Sanofi became disillusioned about the prospects of KB001? \u00a0Or was it an internal strategic decision based on portfolio-review where KB001 just no longer made the cut? The results of the Global\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"KB Part 2 NEW","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KB-Part-2-NEW.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KB-Part-2-NEW.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KB-Part-2-NEW.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2466,"url":"https:\/\/allphasepharma.com\/dir\/2016\/05\/03\/2466\/solithromycin-cap-study-cap-the-details-in-the-publication\/","url_meta":{"origin":4501,"position":2},"title":"Solithromycin CAP Study: \u00a0Cap the Details (in the Publication)","author":"Harald","date":"May 3, 2016","format":false,"excerpt":"In a recent publication, the results of a large Phase 3 trial comparing solithromycin with moxifloxacin in the treatment of CAP are presented\u00a0[1]. As this was a global registration trial, we should refer to the indication as CABP, the current FDA acronym for a very defined entity which has some\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Solitair ORAL - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/Solitair-ORAL-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/Solitair-ORAL-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/04\/Solitair-ORAL-slider-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1757,"url":"https:\/\/allphasepharma.com\/dir\/2015\/07\/21\/1757\/the-demise-of-kb001-part-i-an-anti-pseudomonas-antibody-hits-the-dust-instead-of-paydirt\/","url_meta":{"origin":4501,"position":3},"title":"The Demise of KB001 (Part 1): An Anti-Pseudomonas Antibody Hits the Dust (Instead of Paydirt)","author":"Harald","date":"July 21, 2015","format":false,"excerpt":"In January this year, Kalobios informed investors that KB001-A had failed to meet efficacy criteria in a Phase 2 trial of cystic fibrosis (CF) patients.\u00a0 In this well-controlled well-executed placebo-controlled trial of182 patients, the primary endpoint and just about every other efficacy endpoint of interest was missed.\u00a0 Neither did KB001\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"KaloBios slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KaloBios-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KaloBios-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/KaloBios-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1722,"url":"https:\/\/allphasepharma.com\/dir\/2015\/07\/15\/1722\/streptomyces-the-industrious-antibiotic-producer\/","url_meta":{"origin":4501,"position":4},"title":"Streptomyces \u2013 The Industrious Antibiotic Producer","author":"Harald","date":"July 15, 2015","format":false,"excerpt":"Like other\u00a0actinomycetes, the Streptomyces group of microbes straddles the somewhat artificial boundary between bacteria and fungi.\u00a0Growth on culture plates looks 'fungal' and the organism produces spores and germtubes that look like mycelia.\u00a0 Nonetheless these soil organisms are bacteria and of great interest to microbiologists as the producers of many antibiotics\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Streptomyces slider-2 copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/Streptomyces-slider-2-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/Streptomyces-slider-2-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/Streptomyces-slider-2-copy.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1265,"url":"https:\/\/allphasepharma.com\/dir\/2015\/02\/11\/1265\/commenting-on-comments-the-ceftaroline-trial-program-in-cabp\/","url_meta":{"origin":4501,"position":5},"title":"Commenting on Comments:\u00a0 The Ceftaroline Trial Program in CABP","author":"Harald","date":"February 11, 2015","format":false,"excerpt":"The ceftaroline (Teflaro\u00ae) program was executed at a time when FDA was debating a new CABP Guidance with new outcome measures: no longer was the time-honored TOC assessment acceptable, instead improvement on Day 3-5 was to become the new primary endpoint.\u00a0 FDA made other significant changes to the old 1998\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"Teflaro Ad CAP","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/02\/Teflaro-Ad-CAP.jpg?resize=700%2C400 2x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=4501"}],"version-history":[{"count":8,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4501\/revisions"}],"predecessor-version":[{"id":4519,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/4501\/revisions\/4519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/4511"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=4501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=4501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=4501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}